Riyadh — King Faisal Specialist Hospital & Research Centre (KFSHRC) signed five international agreements to boost innovation in biotechnology and digital health during the Saudi-U.S. Investment Forum 2025, reflecting the Kingdom’s continued push to localize advanced medical technologies.
CEO Dr. Majid Al Fayyadh praised the unwavering support from King Salman and Crown Prince Mohammed bin Salman, which he said has enabled the hospital’s transformation into a global medical leader.
Speaking at a high-level roundtable titled “Next-Gen Healthcare: Saudi-U.S. Cooperation in Biotech and Digital Health,” Al Fayyadh outlined the hospital’s strategic goals—clinical excellence, research expansion, academic development, and financial sustainability—all aligned with Vision 2030.
The signed agreements include:
– A MoU with Cleveland Clinic targeting autism and neuroscience
– A tripartite deal with Qiddiya Investment Company and Cleveland Clinic in sports medicine and performance
– A collaboration with Germfree to develop advanced labs
– A deal with Medtronic to establish a new catheterization center and supply cardiac equipment
– A biotech MoU with ImmunityBio, the King Abdullah International Medical Research Center, and the Ministry of Investment to advance immunotherapy for cancer and infectious diseases
Al Fayyadh emphasized that investing in T-cell therapies, robotic surgery, and precision medicine is reducing outbound medical travel and positioning Saudi Arabia as a regional hub for specialized care.
KFSHRC was ranked #1 in the Middle East and Africa and #15 globally among academic medical centers in 2025, and holds the title of most valuable healthcare brand in the region, according to Brand Finance. It also featured on Newsweek’s list of the World’s Smartest Hospitals.
